Search Results - "HOLYOAKE, T. L."

Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem progenitor cells by Allan, E K, Holyoake, T L, Craig, A R, Jørgensen, H G

“…Chronic myeloid leukaemia (CML) is maintained by a rare population of tyrosine kinase inhibitor (TKI)-insensitive malignant stem cells. Our long-term aim is to…”
Get full text

Nilotinib concentration in cell lines and primary CD34 chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters by Davies, A, Jordanides, N E, Giannoudis, A, Lucas, C M, Hatziieremia, S, Harris, R J, Jørgensen, H G, Holyoake, T L, Pirmohamed, M, Clark, R E, Mountford, J C

“…Imatinib mesylate and nilotinib are highly effective at eradicating the majority of chronic myeloid leukemia (CML) cells; however, neither agent induces…”
Get full text

Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors by Konig, H, Holtz, M, Modi, H, Manley, P, Holyoake, T L, Forman, S J, Bhatia, R

“…The therapeutic success of imatinib in chronic myeloid leukemia (CML) is hampered by persistence of malignant stem cells. We investigated whether nilotinib, a…”
Get full text

The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem progenitor cells by Pellicano, F, Šimara, P, Sinclair, A, Helgason, G V, Copland, M, Grant, S, Holyoake, T L

“…The cytotoxic farnesyl transferase inhibitor BMS-214662 has been shown to potently induce mitochondrial apoptosis in primitive CD34+ chronic myeloid leukaemia…”
Get full text

Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease by EISTERER, W, JIANG, X, AUEWARAKUL, C, BARNETT, M. J, EAVES, C. J, EAVES, A. C, CHRIST, O, GLIMM, H, LEE, K. H, PANG, E, LAMBIE, K, SHAW, G, HOLYOAKE, T. L, PETZER, A. L

“…Xenograft models of chronic phase human chronic myeloid leukemia (CML) have been difficult to develop because of the persistence of normal hematopoietic stem…”
Get full text

Gfi-1 inhibits proliferation and colony formation of p210BCR/ABL-expressing cells via transcriptional repression of STAT 5 and Mcl-1 by Soliera, A R, Mariani, S A, Audia, A, Lidonnici, M R, Addya, S, Ferrari-Amorotti, G, Cattelani, S, Manzotti, G, Fragliasso, V, Peterson, L, Perini, G, Holyoake, T L, Calabretta, B

“…Expression of the transcription repressor Gfi-1 is required for the maintenance of murine hematopoietic stem cells. In human cells, ectopic expression of Gfi-1…”
Get full text

A prospective study of real-time panfungal PCR for the early diagnosis of invasive fungal infection in haemato-oncology patients by JORDANIDES, N. E, ALLAN, E. K, MCLINTOCK, L. A, COPLAND, M, DEVANEY, M, STEWART, K, PARKER, A. N, JOHNSON, P. R. E, HOLYOAKE, T. L, JONES, B. L

“…A blinded prospective study was performed to determine whether screening of whole blood using a real-time, panfungal polymerase chain reaction (PCR) technique…”
Get full text

Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia by HOLYOAKE, T. L, JIANG, X, DRUMMOND, M. W, EAVES, A. C, EAVES, C. J

“…Chronic myeloid leukemia (CML) has been studied intensively for many years; yet its treatment remains problematic and its biology remains elusive. In chronic…”
Get full text

Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro by JØRGENSEN, H. G, ALLAN, E. K, GRAHAM, S. M, GODDEN, J. L, RICHMOND, L, ELLIOTT, M. A, MOUNTFORD, J. C, EAVES, C. J, HOLYOAKE, T. L

“…Recent studies indicate that a rare population of primitive quiescent BCR-ABL(+) cells are innately insensitive to imatinib mesylate (IM) and persist after IM…”
Get full text

Targeting survival pathways in chronic myeloid leukaemia stem cells by Sinclair, A, Latif, A L, Holyoake, T L

“…Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disorder characterized by the presence of a fusion oncogene BCR‐ABL, which encodes a protein…”
Get full text

No strong relationship between mannan binding lectin or plasma ficolins and chemotherapy‐related infections by KILPATRICK, D. C., MCLINTOCK, L. A., ALLAN, E. K., COPLAND, M., FUJITA, T., JORDANIDES, N. E., KOCH, C., MATSUSHITA, M., SHIRAKI, H., STEWART, K., TSUJIMURA, M., TURNER, M. L., FRANKLIN, I. M., HOLYOAKE, T. L.

“…SUMMARY Chemotherapy causes neutropenia and an increased susceptibility to infection. Recent reports indicate that mannan‐binding lectin (MBL) insufficiency is…”
Get full text

A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease by Horne, G. A., Stobo, J., Kelly, C., Mukhopadhyay, A., Latif, A. L., Dixon-Hughes, J., McMahon, L., Cony-Makhoul, P., Byrne, J., Smith, G., Koschmieder, S., BrÜmmendorf, T. H., Schafhausen, P., Gallipoli, P., Thomson, F., Cong, W., Clark, R. E., Milojkovic, D., Helgason, G. V., Foroni, L., Nicolini, F. E., Holyoake, T. L., Copland, M.

“…In chronic-phase chronic myeloid leukaemia (CP-CML), residual BCR-ABL1 + leukaemia stem cells are responsible for disease persistence despite TKI. Based on in…”
Get full text

Immature monocytes from G-CSF-mobilized peripheral blood stem cell collections carry surface-bound IL-10 and have the potential to modulate alloreactivity by Fraser, A. R., Cook, G., Franklin, I. M., Templeton, J. G., Campbell, M., Holyoake, T. L., Campbell, J. D. M.

“…Production of the anti‐inflammatory cytokine IL‐10 by monocytes has been implicated as a probable negative regulator of graft‐versus‐host disease (GvHD) in…”
Get full text

Dysregulated expression of the major telomerase components in leukaemic stem cells by DRUMMOND, M. W, HOARE, S. F, MONAGHAN, A, GRAHAM, S. M, ALCORN, M. J, KEITH, W. N, HOLYOAKE, T. L

“…Telomere loss is rapid during the progression of chronic myeloid leukaemia (CML) and correlates with prognosis. We therefore sought to measure expression of…”
Get full text

Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry by Brümmendorf, Tim H., Holyoake, Tessa L., Rufer, Nathalie, Barnett, Michael J., Schulzer, Michael, Eaves, Connie J., Eaves, Allen C., Lansdorp, Peter M.

“…Chronic myeloid leukemia (CML) is a clonal, multilineage myeloproliferative disorder characterized by the Philadelphia chromosome (Ph) and a marked expansion…”
Get full text

Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia by COPLAND, M, FRASER, A. R, HARRISON, S. J, HOLYOAKE, T. L

“…Standard allogeneic stem cell transplantation (alloSCT) has provided a cure for chronic myeloid leukaemia (CML) over the last 25 years, but is only an option…”
Get full text

Successful haemopoietic stem cell transplantation does not correct mannan-binding lectin deficiency by KILPATRICK, D. C, STEWART, K, ALLAN, E. K, MCLINTOCK, L. A, HOLYOAKE, T. L, TURNER, M. L

“…It has been reported that in allogeneic stem cell transplantation, the mannan-binding lectin (MBL) status of the donor has prognostic value for the recipient…”
Get full text

Is there a cloud in the silver lining for imatinib? by PATERSON, S. C, SMITH, K. D, HOLYOAKE, T. L, JORGENSEN, H. G

“…Imatinib mesylate (Gleevec) or Glivec), a small molecule tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia, has been said to herald the…”
Get full text

Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones by CHEE, Y. L, VICKERS, M. A, STEVENSON, D, HOLYOAKE, T. L, CULLIGAN, D. J

“…Leukemia (2003) 17, 634-635. doi:10.1038/sj.leu.2402842…”
Get full text

CD34-positive cells isolated from cryopreserved peripheral-blood progenitor cells can be expanded ex vivo and used for transplantation with little or no toxicity by Alcorn, M J, Holyoake, T L, Richmond, L, Pearson, C, Farrell, E, Kyle, B, Dunlop, D J, Fitzsimons, E, Steward, W P, Pragnell, I B, Franklin, I M

“…The objectives of this phase I study were to assess the feasibility of using cryopreserved peripheral-blood progenitor cells (PBPC) for large-scale CD34…”
Get more information